Li S Y, Teh B S, Seow W K, Liu Y L, Thong Y H
Department of Child Health, University of Queensland, Mater Childrens Hospital, South Brisbane, Australia.
Int J Immunopharmacol. 1991;13(2-3):129-34. doi: 10.1016/0192-0561(91)90089-p.
A novel flavonoid compound baohuoside-1 (3,5,7-trihydroxy-4'-methoxyl-8-prenylflavone-3-O-alpha-L-rhamnopy ranoside) was investigated for immunopharmacological properties in vitro. The results show that baohuoside-1 has significant suppressive effects on neutrophil chemotaxis, mitogen-induced lymphocyte transformation, mixed-lymphocyte culture, NK-cell cytotoxicity and IL-2 production. These dose-dependent inhibitory effects were found to be significant at concentrations of less than 1 microgram/ml, compared with greater than 94% cell viability at concentrations of 10 micrograms/ml. These results suggest that baohuoside-1 may have potential as an anti-inflammatory/immunosuppressive agent.
研究了一种新型黄酮类化合物宝藿苷-1（3,5,7-三羟基-4'-甲氧基-8-异戊烯基黄酮-3-O-α-L-鼠李糖苷）的体外免疫药理学特性。结果表明，宝藿苷-1对中性粒细胞趋化性、丝裂原诱导的淋巴细胞转化、混合淋巴细胞培养、NK细胞细胞毒性及白细胞介素-2的产生均有显著抑制作用。与10微克/毫升浓度时细胞存活率大于94%相比，在浓度低于1微克/毫升时发现这些剂量依赖性抑制作用显著。这些结果提示，宝藿苷-1可能具有作为抗炎/免疫抑制剂的潜力。
